Top

Published in:

01-05-2020 | Chronic Lymphocytic Leukemia | Original Article

Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia

Authors: Denise Risnik, Ana Colado, Enrique Podaza, María Belén Almejún, Esteban Enrique Elías, Raimundo Fernando Bezares, Horacio Fernández-Grecco, Noé Seija, Pablo Oppezzo, Mercedes Borge, Romina Gamberale, Mirta Giordano

Published in: Cancer Immunology, Immunotherapy | Issue 5/2020

Abstract

Despite significant therapeutic improvements chronic lymphocytic leukemia (CLL) remains an incurable disease and there is a persistent pursuit of new treatment alternatives. Lurbinectedin, a selective inhibitor of active transcription of protein-coding genes, is currently in phase II/III clinical trials for solid tumors such as small-cell lung cancer (SCLC). In this study, we aimed to evaluate the activity of Lurbinectedin on circulating mononuclear cells from CLL patients and to determine whether Lurbinectedin could affect the cross-talk between B-CLL cells and the tumor microenvironment. We found that Lurbinectedin induced a dose- and time-dependent death in all cell types evaluated, with B cells, monocytes and monocytic myeloid derived suppressor cells (Mo-MDSC) being the most susceptible populations. At sub-apoptotic doses, Lurbinectedin decreased the expression of CCR7 in B-CLL cells and impaired their migration towards CCL19 and CCL21. Furthermore, low concentrations of Lurbinectedin stimulated the synthesis of pro-IL1β in monocytes and nurse-like cells, without inducing the inflammasome activation. Altogether, these results indicate that Lurbinectedin might have antitumor activity in CLL due to its direct action on leukemic cells in combination with its effects on the tumor microenvironment. Our findings encourage further investigation of Lurbinectedin as a potential therapy for CLL.

Available only for authorised users

Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352:804–815. https://doi.org/10.1056/NEJMra041720 CrossRefPubMed

Dighiero G, Hamblin TJ (2008) Chronic lymphocytic leukaemia. Lancet (London, England) 371:1017–1029. https://doi.org/10.1016/S0140-6736(08)60456-0 CrossRef

Cramer P, Langerbeins P, Eichhorst B, Hallek M (2016) Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). Eur J Haematol 96:9–18. https://doi.org/10.1111/ejh.12678 CrossRefPubMed

Ghia P, Circosta P, Scielzo C et al (2005) Differential effects on CLL cell survival exerted by different microenvironmental elements. Curr Top Microbiol Immunol 294:135–145PubMed

Caligaris-Cappio F, Bertilaccio MTS, Scielzo C (2014) How the microenvironment wires the natural history of chronic lymphocytic leukemia. Semin Cancer Biol 24:43–48. https://doi.org/10.1016/j.semcancer.2013.06.010 CrossRefPubMed

Kurtova AV, Balakrishnan K, Chen R et al (2009) Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 114:4441–4450. https://doi.org/10.1182/blood-2009-07-233718 CrossRefPubMedPubMedCentral

Burger JA, Tsukada N, Burger M et al (2000) Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96:2655–2663. https://doi.org/10.1182/blood.V96.8.2655 CrossRefPubMed

Caligaris-Cappio F (2003) Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 123:380–388CrossRefPubMed

Redondo-Muñoz J, García-Pardo A, Teixidó J (2019) Molecular players in hematologic tumor cell trafficking. Front Immunol. https://doi.org/10.3389/fimmu.2019.00156 CrossRefPubMedPubMedCentral

10.

de Rooij MFM, Kuil A, Geest CR et al (2012) The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119:2590–2594. https://doi.org/10.1182/blood-2011-11-390989 CrossRefPubMed

11.

Leal JFM, Martínez-Díez M, García-Hernández V et al (2010) PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol 161:1099–1110. https://doi.org/10.1111/j.1476-5381.2010.00945.x CrossRefPubMedPubMedCentral

12.

Santamaría Nuñez G, Robles CMG, Giraudon C et al (2016) Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells. Mol Cancer Ther 15:1–14. https://doi.org/10.1158/1535-7163.MCT-16-0172 CrossRef

13.

Huang P, Plunkett W (1991) Action of 9-beta-d-arabinofuranosyl-2-fluoroadenine on RNA metabolism. Mol Pharmacol 39:449–455PubMed

14.

Huang P, Sandoval A, Van Den Neste E et al (2000) Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia 14:1405–1413CrossRefPubMed

15.

Belgiovine C, Bello E, Liguori M et al (2017) Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer 117:628–638. https://doi.org/10.1038/bjc.2017.205 CrossRefPubMedPubMedCentral

16.

Kuroda H, Mabuchi S, Kozasa K et al (2017) PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo. Immunotherapy 9:805–817. https://doi.org/10.2217/imt-2017-0046 CrossRefPubMed

17.

Risnik D, Podaza E, Almejún MB et al (2017) Revisiting the role of interleukin-8 in chronic lymphocytic leukemia. Sci Rep 7:15714. https://doi.org/10.1038/s41598-017-15953-x CrossRefPubMedPubMedCentral

18.

Berhanu D, Mortari F, De Rosa SC, Roederer M (2003) Optimized lymphocyte isolation methods for analysis of chemokine receptor expression. J Immunol Methods 279:199–207CrossRefPubMed

19.

Colado A, Almejún MB, Podaza E et al (2017) The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients. Cancer Immunol Immunother 66:461–473. https://doi.org/10.1007/s00262-016-1946-y CrossRefPubMed

20.

Niemann CU, Herman SEM, Maric I et al (2016) Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib—findings from an investigator-initiated phase II study. Clin Cancer Res 22:1572–1582. https://doi.org/10.1158/1078-0432.CCR-15-1965 CrossRefPubMed

21.

Podaza E, Risnik D, Colado A et al (2019) Chronic lymphocytic leukemia cells increase neutrophils survival and promote their differentiation into CD16 high CD62L dim immunosuppressive subset. Int J Cancer 144:1128–1134. https://doi.org/10.1002/ijc.31762 CrossRefPubMed

22.

Elez ME, Tabernero J, Geary D et al (2014) First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. Clin Cancer Res 20:2205–2214. https://doi.org/10.1158/1078-0432.CCR-13-1880 CrossRefPubMed

23.

Fernandez-Teruel C, Gonzalez I, Trocóniz IF et al (2019) Population-pharmacokinetic and covariate analysis of Lurbinectedin (PM01183), a new RNA polymerase II inhibitor, in pooled phase I/II trials in patients with cancer. Clin Pharmacokinet 58:363–374. https://doi.org/10.1007/s40262-018-0701-2 CrossRefPubMed

24.

Liu J, Zhou Y, Huang Q, Qiu L (2015) CD14+HLA-DRlow/- expression: a novel prognostic factor in chronic lymphocytic leukemia. Oncol Lett 9:1167–1172. https://doi.org/10.3892/ol.2014.2808 CrossRefPubMed

25.

Jitschin R, Braun M, Büttner M et al (2014) CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood 124:750–760. https://doi.org/10.1182/blood-2013-12-546416 CrossRefPubMed

26.

Patten PEM, Buggins AGS, Richards J et al (2008) CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 111:5173–5181. https://doi.org/10.1182/blood-2007-08-108605 CrossRefPubMed

27.

Burger JA, Gribben JG (2014) The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol 24:71–81. https://doi.org/10.1016/j.semcancer.2013.08.011 CrossRefPubMed

28.

Elías EE, Almejún MB, Colado A et al (2018) Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies. Haematologica 103:e458–e461. https://doi.org/10.3324/HAEMATOL.2018.188680 CrossRefPubMedPubMedCentral

29.

Till KJ, Lin K, Zuzel M, Cawley JC (2002) The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood 99:2977–2984CrossRefPubMed

30.

Lopez-Giral S, Quintana NE, Cabrerizo M et al (2004) Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol 76:462–471. https://doi.org/10.1189/jlb.1203652.1 CrossRefPubMed

31.

Ghiringhelli F, Bruchard M, Apetoh L (2013) Immune effects of 5-fluorouracil: ambivalence matters. Oncoimmunology 2:e23139CrossRefPubMedPubMedCentral

32.

Shurin MR (2013) Dual role of immunomodulation by anticancer chemotherapy. Nat Med 19:20–22. https://doi.org/10.1038/nm.3045 CrossRefPubMedPubMedCentral

33.

Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G (2009) The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 10:241–247. https://doi.org/10.1038/ni.1703 CrossRefPubMedPubMedCentral

34.

Yan X-J, Dozmorov I, Li W et al (2011) Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. Blood 118:5201–5210. https://doi.org/10.1182/blood-2011-03-342436 CrossRefPubMedPubMedCentral

35.

Netea MG, Nold-Petry CA, Nold MF et al (2009) Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 113:2324–2335. https://doi.org/10.1182/blood-2008-03-146720 CrossRefPubMedPubMedCentral

36.

Podaza E, Sabbione F, Risnik D et al (2017) Neutrophils from chronic lymphocytic leukemia patients exhibit an increased capacity to release extracellular traps (NETs). Cancer Immunol Immunother. https://doi.org/10.1007/s00262-016-1921-7 CrossRefPubMed

37.

Herishanu Y, Kay S, Sarid N et al (2013) Absolute monocyte count trichotomizes chronic lymphocytic leukemia into high risk patients with immune dysregulation, disease progression and poor survival. Leuk Res 37:1222–1228. https://doi.org/10.1016/j.leukres.2013.07.017 CrossRefPubMed

38.

Friedman DR, Sibley AB, Owzar K et al (2016) Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. Am J Hematol 91:687–691. https://doi.org/10.1002/ajh.24376 CrossRefPubMedPubMedCentral

39.

Nishio M, Endo T, Tsukada N et al (2005) Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 106:1012–1020. https://doi.org/10.1182/blood-2004-03-0889 CrossRefPubMedPubMedCentral

40.

Lohmann G, Vasyutina E, Bloehdorn J et al (2017) Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia. Leukemia 31:1177–1186. https://doi.org/10.1038/leu.2016.294 CrossRefPubMed

41.

Hulkkonen J, Vilpo J, Vilpo L et al (2000) Interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters. Haematologica 85:600–606PubMed

42.

Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8:942–949. https://doi.org/10.1038/ni1496 CrossRefPubMed

43.

Pang N, Zhang R, Li J et al (2016) Increased IL-10/IL-17 ratio is aggravated along with the prognosis of patients with chronic lymphocytic leukemia. Int Immunopharmacol 40:57–64. https://doi.org/10.1016/j.intimp.2016.07.008 CrossRefPubMed

44.

Jain P, Javdan M, Feger FK et al (2012) Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica 97:599–607. https://doi.org/10.3324/haematol.2011.047316 CrossRefPubMedPubMedCentral

Title: Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia
Authors: Denise Risnik
Ana Colado
Enrique Podaza
María Belén Almejún
Esteban Enrique Elías
Raimundo Fernando Bezares
Horacio Fernández-Grecco
Noé Seija
Pablo Oppezzo
Mercedes Borge
Romina Gamberale
Mirta Giordano
Publication date: 01-05-2020
Publisher: Springer Berlin Heidelberg
Keyword: Chronic Lymphocytic Leukemia
Published in: Cancer Immunology, Immunotherapy / Issue 5/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02513-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2020

Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density

Long-term surviving cancer patients as a source of therapeutic TCR

Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8-positive cytotoxic lymphocytes

Current progress in NK cell biology and NK cell-based cancer immunotherapy

CD160 expression on CD8+ T cells is associated with active effector responses but limited activation potential in pancreatic cancer

Nonlinear response to cancer nanotherapy due to macrophage interactions revealed by mathematical modeling and evaluated in a murine model via CRISPR-modulated macrophage polarization

Keynote webinar | Spotlight on antibody–drug conjugates in cancer